Funding for endolysin technology to replace antibiotics

funding for endolysin technology to replace antibiotics

Dutch biotechnology company, Micreos has raised €30 million for endolysin technology to replace antibiotics.

The funding is to accelerate the development of its endolysin technology, which is says is set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its OTC Gladskin product for eczema.

According to the World Health Organization, antibiotic resistance is one of the world’s biggest health threats. The call for true alternatives is more pressing than ever. Antibiotics do not distinguish between bad and good bacteria, and their use induces resistance.

Endolysins have three distinct features:

  1. Ability to target only unwanted bacteria while preserving the microbiome, which is essential for our health.
  2. Ability to kill antibiotic resistant strains of bacteria.
  3. Emergence of resistance against endolysins is not expected.

Endolysin technology opens a new therapeutic window for treatment of chronic inflammatory conditions, such as atopic dermatitis and persistent wound infections, including those caused by MRSA.

Micreos’ Staphefekt™ SA.100, is the world’s first endolysin approved for human use. It selectively targets Staphylococcus aureus – often referred to as ‘Staph’ – which is a major trigger of eczema and other inflammatory skin conditions.

The €30 million funding includes a non-dilutive €5.4 million Innovation Credit granted by the Dutch Ministry of Economic Affairs. Micreos has conducted several studies with Gladskin, including trials on eczema, acne and rosacea. Studies in orphan indications with a high unmet need, like primary immune deficiencies and Netherton disease are ongoing.

Micreos Chief Executive Officer Mark Offerhaus noted: “This funding from existing and new investors will advance the adoption of our endolysin technology and help us reach the millions who stand to benefit. We are exploring partnerships to further accelerate the commercialization of our technology.”